Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380237 | 0.86 | MEN1 (0.44) | MEN1KMT2AALDH1A1LIPCLIPG | |
| SCHEMBL7388602 | 0.83 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4050662 | 0.80 | RXFP1 (0.51) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2432349 | 0.80 | GAA (0.51) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19358889 | 0.78 | KIF11 (0.56) | MEN1KMT2AALDH1A1LIPCLIPG | |
| SCHEMBL17796948 | 0.77 | TAS2R14 (0.48) | MEN1KMT2AALDH1A1LIPCLIPG | |
| SCHEMBL16060789 | 0.77 | KDM4E (0.57) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17797034 | 0.76 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1MAPTTAS2R14 | |
| SCHEMBL17220661 | 0.76 | MEN1 (0.47) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL12894743 | 0.75 | PTPN5 (0.41) | MEN1KMT2ALIPCLIPGCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | claimed |
| US-7179909-B2 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | claimed |
| EP-1694658-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | Aventis Pharma S.A. (FR) | 2006-08-30 | — | — | EP | claimed |
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| WO-2005066146-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO[3,4,5-DE][4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA S.A. (FR) | 2005-07-21 | — | — | WO | claimed |
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7179909-B2 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | disclosed |
| EP-1694658-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | Aventis Pharma S.A. (FR) | 2006-08-30 | — | — | EP | disclosed |
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | disclosed |
| WO-2005066146-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO[3,4,5-DE][4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA S.A. (FR) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | CYP2S1, CYP3A4, CYP2D6 | MEN1 3440/4885KMT2A 1405/4885ALDH1A1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.